ACHL News

The IPO market pumped the brakes in the shortened holiday week, with six IPOs raising $1.9 billion and just two SPACs raising $300 million. Pipeline activity slowed from previous weeks as well, with six IPOs and seven SPACs submitting initial filings. Low-cost airline Frontier Group Holdings (ULCC) priced at the low end to raise $570 million at a $4.3 billion...read more

Achilles Therapeutics, a Phase 1/2 biotech developing precision T cell therapies for solid tumors, raised $176 million by offering 9.8 million ADSs at $18, within the range of $17 to $19. The company's pipeline contains cNeT candidate ATL001, which is currently being evaluated in two open-label Phase 1/2a trials for advanced NSCLC and metastatic or recurrent melanoma, with...read more

Following some turbulence in the IPO market, eight IPOs are scheduled to raise $3.0 billion in the shortened holiday week. Online real estate brokerage Compass (COMP) plans to raise $882 million at a $12.5 billion market cap. Compass provides a platform for real estate agents to manage and deliver service to seller and buyer clients. Fast growing but...read more

Achilles Therapeutics, a Phase 1/2 biotech developing precision T cell therapies for solid tumors, announced terms for its IPO on Thursday. The London, UK-based company plans to raise $176 million by offering 9.8 million ADSs at a price range of $17 to $19. At the midpoint of the proposed range, Achilles Therapeutics would command a fully diluted market value of $734 million. ...read more